Glutaminolysis, but not glycolysis, is reduced in Plasmax-cultured ENO1-deleted glioma cells corresponding to the absence of in vivo efficacy of glutaminolysis inhibitor CB-839.In standard DMEM medium, cells with and without ENO1 deletion were equally sensitive to CB-839 treatment. The gene discussed is ENO1; the disease is central nervous system cancer.